Edwards Lifesciences Corporation
EW
$85.28
-$1.90-2.18%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.75% | 25.71% | -26.90% | -21.50% | -21.29% |
| Total Depreciation and Amortization | 29.64% | 36.41% | -22.61% | -19.77% | -16.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 330.81% | 205.15% | 108.71% | 18.44% | 27.16% |
| Change in Net Operating Assets | 116.40% | 19.13% | -6.69% | 33.55% | -79.16% |
| Cash from Operations | 194.15% | 26.09% | -8.22% | 65.88% | -39.46% |
| Capital Expenditure | -29.78% | 11.05% | 47.30% | 25.55% | 20.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -748.26% | -748.26% | -748.26% | -213.24% |
| Divestitures | -98.92% | -- | -- | -- | -- |
| Other Investing Activities | 87.03% | -1,241.24% | -867.22% | -950.76% | -831.32% |
| Cash from Investing | -130.82% | -137.58% | 600.41% | 887.77% | 1,230.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 20.07% | 13.90% | -26.09% | -30.14% | -14.66% |
| Repurchase of Common Stock | -464.02% | -40.58% | 59.77% | 25.96% | 81.99% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3,445.07% | -2,703.33% | -70.49% | 447.83% | 646.15% |
| Cash from Financing | 2.67% | 35.65% | -95.03% | -194.26% | -38.26% |
| Foreign Exchange rate Adjustments | -149.72% | -92.44% | -91.76% | 104.23% | 436.31% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -106.24% | -143.56% | 167.26% | 444.47% | 409.00% |